Insurers deny whole exome sequencing for undiagnosed rare disease patients, forcing years of costlier diagnostic dead-ends

When a child presents with unexplained developmental delays, seizures, or multi-system symptoms that don't match any common condition, the single most informative diagnostic test is whole exome sequencing (WES), which reads all 20,000 protein-coding genes at once. It costs between $5,000 and $12,000. Yet insurance companies deny prior authorization for WES approximately 18% of the time, often classifying it as "experimental" or "investigational" despite it being in clinical use since 2011 and now standard practice at every major academic medical center. The downstream cost of this denial is staggering. When researchers at UCLA and other institutions studied 147 patients whose WES was denied by insurance, 53.7% had at least one diagnostic or candidate finding and 10.9% had a clinically diagnostic result that immediately changed medical management. Those patients would have gotten their answer in weeks. Instead, they spent years cycling through specialist after specialist, racking up MRIs, biopsies, metabolic panels, and hospital admissions that individually cost more than the denied test. The average rare disease patient sees 8 or more doctors over 4.7 years before diagnosis. Each misdiagnosis isn't just a billing event -- it's a wrong treatment, a side effect, a lost year of a child's development. This problem persists because insurance utilization management criteria lag behind clinical practice by a decade. The coverage determination committees that write these policies rely on outdated evidence standards and don't update them until forced by regulation or litigation. Private insurers are significantly more likely to deny WES than public insurance programs, because private plans face less regulatory pressure to cover advanced diagnostics. Meanwhile, the patients who suffer most are those with the rarest conditions -- the ones whose symptoms don't match any textbook, who fall through every diagnostic algorithm, and whose only realistic path to an answer is broad genomic testing that their insurer refuses to pay for.